Deloitte Recap LLC: biopharma business intelligence subscription tools and consulting services

Subscriber Login
- Recap IQ Series by Deloitte
- DEAL builder
- VALUATION analyzer
- DEVELOPMENT optimizer
- Recap Basic

Allicense Conference

Allicense 2012

Date:
May 1-2, 2012

Location:
Palace Hotel, San Francisco

Early Bird Registration Open Right Arrow

Special Report

Report Shows mAbs Are Taking Longer to Develop

How U.S. Biotechnology Companies Pioneered the Path to Clinical, Regulatory and Market Success for Monoclonal Antibodies

Order Now

Special Report

What’s the Deal with Monoclonal Antibodies?

Order Now

White Papers and Case Studies

Case Study
Buy-Side Due Diligence – How milestone payments & post-launch Effective Royalty Rates factor into a company’s value.
Register to Receive Right Arrow

White Paper
Innovative Strategies for Oncology Drug Development - How biotech companies have won a growing share of oncology drug approvals.
Register to Receive Right Arrow

Calistoga: Deloitte Recap’s DEAL builder™ ‘Valuable Tool’ When Plotting Campaign for Partner

In Wake of Acquisition by Gilead

We spoke with Aaron Coe, former director of corporate development and strategic planning at Calistoga Pharmaceuticals (Calistoga), to understand his experiences using DEAL builder, which played an important role in keeping the Calistoga management team informed during the strategic planning and execution of a robust partnering campaign between Calistoga and Gilead Science. The effort ended with Gilead Science’s structured buyout of Calistoga, an agreement that brought $375 million cash up front and $225 million in potential milestone payments for Calistoga, and gave Gilead access to a promising Phase II cancer compound.

Coe said DEAL builder is “a terrific tool that really helped to inform our management team about the specifics of deals that were done in our space and at various stages of development. This was really helpful as we laid out our strategy and the partnering campaign.”

In the transaction, Gilead gained access to all of Calistoga’s assets and know-how and was able to retain the vast majority of the R&D personnel. Of particular interest to Gilead was Calistoga’s lead candidate CAL-101, which selectively targets...

Read more >>

A Look Back:

10 Deals that Changed Biotech

Commentary:

PTC Therapeutics ...
Quicker FDA Approvals ...

Daily Deal for January 27, 2012

The Daily Deal is a sample, updated daily, of Recap's Deal Snapshots available in the IQ Series.

Deal Snapshots provide a visual overview of the alliance contract terms based on the deal's contract the Deloitte Recap consultants have analyzed and summarized. Access Recap's Deal Snapshots using DEAL builder - decision support for partnering options and how to structure the deal.

DEAL builder subscriber login
Find out how to subscribe

Quarterly Trends for Biotech Out-Licensing Deal Values 2006-2011 Q1

Contributed by the Deloitte Recap consultants

As collectors and analyzers of the data within our databases, the Deloitte Recap consultants are immersed in some of the best alliance data available to understand the latest industry trends.

Access Recap's Effective Royalty Rate Grapher to analyze effective royalty rates for deals by stage of development at signing using VALUATION analyzer - decision support for asset valuation, partnering decisions, and determining effective royalty rates.

VALUATION analyzer subscriber login
Find out how to subscribe

Clinical Development Analysis for January 27, 2012

The Clinical Development Analysis is a sample, updated daily, of Recap's clinical analytics available in the IQ Series.

Access Recap's unique analytics backed by detailed drug development histories using DEVELOPMENT optimizer - decision support for identifying leading practices in clinical development, including attrition and advancement rates, development and regulatory performance, and termination efficiencies. DEVELOPMENT optimizer was designed to support the technical, regulatory, and business development aspects of clinical development.

DEVELOPMENT optimizer subscriber login
Find out how to subscribe